185 related articles for article (PubMed ID: 36206074)
21. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
22. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
23. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
25. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
26. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
[TBL] [Abstract][Full Text] [Related]
27. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
Chowdhury IH; Ojerholm E; McMillan MT; Miller D; Kolker JD; Kurtz G; Dorsey JF; Nagda SN; Geiger GA; Brem S; O'Rourke DM; Zager EL; Gangadhar T; Schuchter L; Lee JY; Alonso-Basanta M
Radiat Oncol; 2015 Dec; 10():248. PubMed ID: 26626714
[TBL] [Abstract][Full Text] [Related]
28. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
29. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review.
van Opijnen MP; Dirven L; Coremans IEM; Taphoorn MJB; Kapiteijn EHW
Int J Cancer; 2020 Mar; 146(6):1479-1489. PubMed ID: 31583684
[TBL] [Abstract][Full Text] [Related]
30. The strategy of repeat stereotactic radiosurgery without whole brain radiation treatment for new brain metastases: Outcomes and implications for follow-up monitoring.
Shen CJ; Rigamonti D; Redmond KJ; Kummerlowe MN; Lim M; Kleinberg LR
Pract Radiat Oncol; 2016; 6(6):409-416. PubMed ID: 27687187
[TBL] [Abstract][Full Text] [Related]
31. Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.
Wegner RE; Abel S; D'Amico RS; Mehta GU; Sheehan J
J Neurooncol; 2021 Mar; 152(1):79-87. PubMed ID: 33432380
[TBL] [Abstract][Full Text] [Related]
32. Developments in therapy for brain metastases in melanoma patients.
Wilkes JG; Patel A; McClure E; Pina Y; Zager JS
Expert Opin Pharmacother; 2021 Aug; 22(11):1443-1453. PubMed ID: 33688795
[No Abstract] [Full Text] [Related]
33. The role of systemic therapy in melanoma brain metastases: a narrative review.
Saleem K; Davar D
Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
35. Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy.
Stokes WA; Binder DC; Jones BL; Oweida AJ; Liu AK; Rusthoven CG; Karam SD
J Neuroimmunol; 2017 Dec; 313():118-122. PubMed ID: 29153603
[TBL] [Abstract][Full Text] [Related]
36. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
[TBL] [Abstract][Full Text] [Related]
37. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.
Rahman R; Cortes A; Niemierko A; Oh KS; Flaherty KT; Lawrence DP; Sullivan RJ; Shih HA
J Neurooncol; 2018 Jun; 138(2):299-306. PubMed ID: 29453679
[TBL] [Abstract][Full Text] [Related]
38. Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review.
Li C; Li K; Zhong S; Tang M; Shi X; Bao Y
Crit Rev Oncol Hematol; 2024 Feb; 194():104227. PubMed ID: 38220124
[TBL] [Abstract][Full Text] [Related]
39. Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
Pelizzari G; Bertoli E; Buriolla S; Vitale MG; Basile D; Palmero L; Zara D; Iacono D; Andrea F; Pascoletti G; Bolzonello S; Garutti M; Fasola G; Puglisi F; Minisini AM
Melanoma Res; 2023 Oct; 33(5):398-405. PubMed ID: 37402350
[TBL] [Abstract][Full Text] [Related]
40. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR
Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
